According to information provided by Centocor, maker of one medication based on ustekinumab, their version of the drug is associated with several types of serious adverse effects. These include an increased risk of infection, such as by [[tuberculosis]] and an increased risk of certain types of [[cancer]]. As with some other immunosuppressant drugs like [[ciclosporin]], the brain swelling of [[posterior reversible encephalopathy syndrome]] is a risk. The pharmaceutical company also reports serious [[allergic reaction]] as a possible side effect. More common side effects are [[upper respiratory infection]], [[headache]], and [[tiredness]].<ref>{{cite web |title=Important Safety Information |date= |work=STELARA® (ustekinumab) |publisher=Janssen Biotech |url=http://www.stelarainfo.com/safety}}</ref>

 


 
Clinical trials have shown that subcutaneous ustekinumab was generally well tolerated. Most treatment-emergent adverse events were of mild severity.<ref name="ustekinu">{{cite journal |vauthors=Weber J, Keam SJ |title=Ustekinumab |journal=BioDrugs |volume=23 |issue=1 |pages=53–61 |year=2009 |pmid=19344192 |doi=10.2165/00063030-200923010-00006 |url=http://adisonline.com/biodrugs/pages/articleviewer.aspx?year=2009&issue=23010&article=00006&type=abstract }}</ref>

 

